Is Novo Nordisk (Ozempic) Stock a good buy in 2026, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NYSE: NVO) stock is to Hold NVO stock.
Out of 2 analysts, 0 (0%) are recommending NVO as a Strong Buy, 0 (0%) are recommending NVO as a Buy, 2 (100%) are recommending NVO as a Hold, 0 (0%) are recommending NVO as a Sell, and 0 (0%) are recommending NVO as a Strong Sell.
According to 2 Wall Street analysts that have issued a 1 year NVO price target, the average NVO price target is $43.50, with the highest NVO stock price forecast at $46.00 and the lowest NVO stock price forecast at $41.00.
On average, Wall Street analysts predict that Novo Nordisk (Ozempic)'s share price could fall to $43.50 by Mar 2, 2027. The average Novo Nordisk (Ozempic) stock price prediction forecasts a potential downside of 7.6% from the current NVO share price of $47.08.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.